SK18452002A3 - Deriváty kumarínu inhibujúce COMT, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie - Google Patents
Deriváty kumarínu inhibujúce COMT, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie Download PDFInfo
- Publication number
- SK18452002A3 SK18452002A3 SK1845-2002A SK18452002A SK18452002A3 SK 18452002 A3 SK18452002 A3 SK 18452002A3 SK 18452002 A SK18452002 A SK 18452002A SK 18452002 A3 SK18452002 A3 SK 18452002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- group
- alkyl
- carbon atoms
- hydroxyl
- compound
- Prior art date
Links
- 108020002739 Catechol O-methyltransferase Proteins 0.000 title claims abstract description 22
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 9
- 102100040999 Catechol O-methyltransferase Human genes 0.000 title claims 3
- 150000001893 coumarin derivatives Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 94
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 53
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 30
- 125000004432 carbon atom Chemical group C* 0.000 claims description 107
- 125000000217 alkyl group Chemical group 0.000 claims description 69
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 64
- -1 nitro, thio, amino Chemical group 0.000 claims description 42
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 229910052736 halogen Inorganic materials 0.000 claims description 25
- 150000002367 halogens Chemical class 0.000 claims description 25
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 15
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 239000001301 oxygen Substances 0.000 claims description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 14
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 125000002947 alkylene group Chemical group 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
- 125000001624 naphthyl group Chemical group 0.000 claims description 10
- 239000011593 sulfur Substances 0.000 claims description 10
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 7
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 7
- 125000004450 alkenylene group Chemical group 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 abstract description 5
- 239000000047 product Substances 0.000 description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- 239000000203 mixture Substances 0.000 description 25
- 239000000243 solution Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- 125000004076 pyridyl group Chemical group 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 11
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 125000001544 thienyl group Chemical group 0.000 description 6
- ZZTFJNNLOBLOPU-UHFFFAOYSA-N 2-hydroxy-3,4-dimethoxy-5-nitrobenzaldehyde Chemical compound COC1=C(O)C(C=O)=CC([N+]([O-])=O)=C1OC ZZTFJNNLOBLOPU-UHFFFAOYSA-N 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 125000002541 furyl group Chemical group 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 125000002757 morpholinyl group Chemical group 0.000 description 5
- 125000004193 piperazinyl group Chemical group 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 150000004775 coumarins Chemical class 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 125000005936 piperidyl group Chemical group 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000004323 potassium nitrate Substances 0.000 description 3
- 235000010333 potassium nitrate Nutrition 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 2
- WNCNWLVQSHZVKV-UHFFFAOYSA-N 2,4,5-trihydroxybenzaldehyde Chemical compound OC1=CC(O)=C(C=O)C=C1O WNCNWLVQSHZVKV-UHFFFAOYSA-N 0.000 description 2
- CVAKRGWBLNNJJI-UHFFFAOYSA-N 5-(2-aminoethyl)-1-methylcyclohexa-2,4-diene-1,2-diol Chemical compound CC1(O)CC(CCN)=CC=C1O CVAKRGWBLNNJJI-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- GGNQRNBDZQJCCN-UHFFFAOYSA-N benzene-1,2,4-triol Chemical compound OC1=CC=C(O)C(O)=C1 GGNQRNBDZQJCCN-UHFFFAOYSA-N 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- BHWOTMCVUUPCPP-UHFFFAOYSA-N ethyl 2-(6,7-dihydroxy-4-methyl-2-oxochromen-3-yl)acetate Chemical compound OC1=C(O)C=C2OC(=O)C(CC(=O)OCC)=C(C)C2=C1 BHWOTMCVUUPCPP-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- FMCAFXHLMUOIGG-JTJHWIPRSA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-JTJHWIPRSA-N 0.000 description 1
- CWWADBFDUPRVIN-UHFFFAOYSA-N (3-acetyloxy-6-oxo-7,8,9,10-tetrahydrobenzo[c]chromen-2-yl) acetate Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(OC(C)=O)C(OC(=O)C)=C1 CWWADBFDUPRVIN-UHFFFAOYSA-N 0.000 description 1
- YBADLXQNJCMBKR-UHFFFAOYSA-N (4-nitrophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C([N+]([O-])=O)C=C1 YBADLXQNJCMBKR-UHFFFAOYSA-N 0.000 description 1
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 description 1
- YMRIDJQAEZFTSC-UHFFFAOYSA-N 2,3-dihydro-1h-tetrazole Chemical group N1NC=NN1 YMRIDJQAEZFTSC-UHFFFAOYSA-N 0.000 description 1
- IAJBQAYHSQIQRE-UHFFFAOYSA-N 2,4,5-trimethoxybenzaldehyde Chemical compound COC1=CC(OC)=C(C=O)C=C1OC IAJBQAYHSQIQRE-UHFFFAOYSA-N 0.000 description 1
- ZFZAFNQYRZGWNK-UHFFFAOYSA-N 2,4-dihydroxy-5-methoxybenzaldehyde Chemical compound COC1=CC(C=O)=C(O)C=C1O ZFZAFNQYRZGWNK-UHFFFAOYSA-N 0.000 description 1
- BGFWNEQCWRXRFO-UHFFFAOYSA-N 2-(6,7-dihydroxy-2-oxochromen-3-yl)acetic acid Chemical compound OC1=C(O)C=C2OC(=O)C(CC(=O)O)=CC2=C1 BGFWNEQCWRXRFO-UHFFFAOYSA-N 0.000 description 1
- DKELHZLAKMOKAR-UHFFFAOYSA-N 2-(6,7-dihydroxy-4-methyl-2-oxochromen-3-yl)acetic acid Chemical compound C1=C(O)C(O)=CC2=C1OC(=O)C(CC(O)=O)=C2C DKELHZLAKMOKAR-UHFFFAOYSA-N 0.000 description 1
- AZJRFTLXUGPYLQ-UHFFFAOYSA-N 2-(6,7-dihydroxy-4-methyl-5-nitro-2-oxochromen-3-yl)acetic acid Chemical compound C1=C(O)C(O)=C([N+]([O-])=O)C2=C1OC(=O)C(CC(O)=O)=C2C AZJRFTLXUGPYLQ-UHFFFAOYSA-N 0.000 description 1
- GFGYIZRADAXSAH-UHFFFAOYSA-N 2-(6,7-dihydroxy-5-nitro-2-oxochromen-3-yl)acetic acid Chemical compound OC1=C(O)C=C2OC(=O)C(CC(=O)O)=CC2=C1[N+]([O-])=O GFGYIZRADAXSAH-UHFFFAOYSA-N 0.000 description 1
- WRELOAXLZIDTAC-UHFFFAOYSA-N 2-[(2,4,5-trimethoxyphenyl)methylidene]butanedioic acid Chemical compound COC1=CC(OC)=C(C=C(CC(O)=O)C(O)=O)C=C1OC WRELOAXLZIDTAC-UHFFFAOYSA-N 0.000 description 1
- UIOMNPYQUBMBOJ-UHFFFAOYSA-N 2-hydroxy-3,4-dimethoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(O)=C1OC UIOMNPYQUBMBOJ-UHFFFAOYSA-N 0.000 description 1
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
- DSMKGOXFBBHSRI-UHFFFAOYSA-N 3-(4-chlorophenyl)-7,8-dimethoxy-6-nitrochromen-2-one Chemical compound O=C1OC2=C(OC)C(OC)=C([N+]([O-])=O)C=C2C=C1C1=CC=C(Cl)C=C1 DSMKGOXFBBHSRI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- VBRQYBXHVKYOPF-UHFFFAOYSA-N 3-benzoyl-6,7-dihydroxy-5-nitrochromen-2-one Chemical compound C=1C=2C([N+]([O-])=O)=C(O)C(O)=CC=2OC(=O)C=1C(=O)C1=CC=CC=C1 VBRQYBXHVKYOPF-UHFFFAOYSA-N 0.000 description 1
- SVXDAGYNZSMVBE-UHFFFAOYSA-N 3-ethoxycarbonyl-4-(2,4,5-trimethoxyphenyl)but-3-enoic acid Chemical compound CCOC(=O)C(CC(O)=O)=CC1=CC(OC)=C(OC)C=C1OC SVXDAGYNZSMVBE-UHFFFAOYSA-N 0.000 description 1
- UNNBMXHASMHOIQ-UHFFFAOYSA-N 4-(2-aminoethyl)-1-methylcyclohexa-3,5-diene-1,2-diol Chemical compound CC1(O)C=CC(CCN)=CC1O UNNBMXHASMHOIQ-UHFFFAOYSA-N 0.000 description 1
- CDPKJZJVTHSESZ-UHFFFAOYSA-N 4-chlorophenylacetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C=C1 CDPKJZJVTHSESZ-UHFFFAOYSA-N 0.000 description 1
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 1
- STCWBNGIVIFZHI-UHFFFAOYSA-N 6,7-dihydroxy-2-oxochromene-3-carboxylic acid Chemical compound OC1=C(O)C=C2OC(=O)C(C(=O)O)=CC2=C1 STCWBNGIVIFZHI-UHFFFAOYSA-N 0.000 description 1
- YIFBZUZHZJJGSX-UHFFFAOYSA-N 6,7-dihydroxy-3-(2H-tetrazol-5-yl)chromen-2-one Chemical compound O=C1OC=2C=C(O)C(O)=CC=2C=C1C=1N=NNN=1 YIFBZUZHZJJGSX-UHFFFAOYSA-N 0.000 description 1
- IJSVLBUFHWZGBU-UHFFFAOYSA-N 6,7-dihydroxy-5-nitro-2-oxochromene-3-carboxylic acid Chemical compound OC1=C(O)C=C2OC(=O)C(C(=O)O)=CC2=C1[N+]([O-])=O IJSVLBUFHWZGBU-UHFFFAOYSA-N 0.000 description 1
- ZXQYRGJIIUEJGU-UHFFFAOYSA-N 6,7-dihydroxy-5-nitro-3-(2H-tetrazol-5-yl)chromen-2-one Chemical compound C=1C=2C([N+]([O-])=O)=C(O)C(O)=CC=2OC(=O)C=1C1=NN=NN1 ZXQYRGJIIUEJGU-UHFFFAOYSA-N 0.000 description 1
- NBUKMJKGRAGSET-UHFFFAOYSA-N 6,7-dihydroxy-8-nitro-2-oxochromene-3-carboxylic acid Chemical compound OC1=C(O)C([N+]([O-])=O)=C2OC(=O)C(C(=O)O)=CC2=C1 NBUKMJKGRAGSET-UHFFFAOYSA-N 0.000 description 1
- SSUKLVYUUBMUMF-UHFFFAOYSA-N 6,7-dihydroxy-8-nitro-3-phenylchromen-2-one Chemical compound O=C1OC=2C([N+]([O-])=O)=C(O)C(O)=CC=2C=C1C1=CC=CC=C1 SSUKLVYUUBMUMF-UHFFFAOYSA-N 0.000 description 1
- LTNZQDCMMYQKKJ-UHFFFAOYSA-N 7,8-dihydroxy-6-nitro-2-oxochromene-3-carboxylic acid Chemical compound [O-][N+](=O)C1=C(O)C(O)=C2OC(=O)C(C(=O)O)=CC2=C1 LTNZQDCMMYQKKJ-UHFFFAOYSA-N 0.000 description 1
- FQPRITIGMQOPDJ-UHFFFAOYSA-N 7,8-dihydroxy-6-nitro-3-(4-nitrophenyl)chromen-2-one Chemical compound C=1C=2C=C([N+]([O-])=O)C(O)=C(O)C=2OC(=O)C=1C1=CC=C([N+]([O-])=O)C=C1 FQPRITIGMQOPDJ-UHFFFAOYSA-N 0.000 description 1
- XBSIVMDCUWIBNZ-UHFFFAOYSA-N 7,8-dihydroxy-6-nitro-3-phenylchromen-2-one Chemical compound C=1C=2C=C([N+]([O-])=O)C(O)=C(O)C=2OC(=O)C=1C1=CC=CC=C1 XBSIVMDCUWIBNZ-UHFFFAOYSA-N 0.000 description 1
- ZSUGYLBUJRVKBG-UHFFFAOYSA-N 7,8-dimethoxy-6-nitro-3-(4-nitrophenyl)chromen-2-one Chemical compound O=C1OC2=C(OC)C(OC)=C([N+]([O-])=O)C=C2C=C1C1=CC=C([N+]([O-])=O)C=C1 ZSUGYLBUJRVKBG-UHFFFAOYSA-N 0.000 description 1
- LUVRRDDKIDROAW-UHFFFAOYSA-N 7,8-dimethoxy-6-nitro-3-phenylchromen-2-one Chemical compound O=C1OC2=C(OC)C(OC)=C([N+]([O-])=O)C=C2C=C1C1=CC=CC=C1 LUVRRDDKIDROAW-UHFFFAOYSA-N 0.000 description 1
- QISOJXZLKJQILH-UHFFFAOYSA-N 7-hydroxy-6-methoxy-8-nitro-2-oxochromene-3-carboxylic acid Chemical compound C1=C(C(O)=O)C(=O)OC2=C1C=C(OC)C(O)=C2[N+]([O-])=O QISOJXZLKJQILH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical group C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 238000006600 Stobbe condensation reaction Methods 0.000 description 1
- DYFPQIYEZQULMZ-XKGORWRGSA-N [(3s)-3-amino-3-carboxypropyl]-[[(2s,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl]-methylsulfanium;chloride Chemical compound [Cl-].O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 DYFPQIYEZQULMZ-XKGORWRGSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- DNAVOCNYHNNEQI-UHFFFAOYSA-N asaronaldehyde Natural products COC1=CC(OC)=C(C=CC=O)C=C1OC DNAVOCNYHNNEQI-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000012649 demethylating agent Substances 0.000 description 1
- TXFOLHZMICYNRM-UHFFFAOYSA-N dichlorophosphoryloxybenzene Chemical compound ClP(Cl)(=O)OC1=CC=CC=C1 TXFOLHZMICYNRM-UHFFFAOYSA-N 0.000 description 1
- NNOGMCQLKMLNPL-UHFFFAOYSA-N diethyl 2-acetylpentanedioate Chemical compound CCOC(=O)CCC(C(C)=O)C(=O)OCC NNOGMCQLKMLNPL-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- NAOHMNNTUFFTBF-UHFFFAOYSA-N ethyl 2-(2h-tetrazol-5-yl)acetate Chemical compound CCOC(=O)CC=1N=NNN=1 NAOHMNNTUFFTBF-UHFFFAOYSA-N 0.000 description 1
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
- JXAIAZYGEYXKGM-UHFFFAOYSA-N ethyl 7,8-dimethoxy-6-nitro-2-oxochromene-3-carboxylate Chemical compound [O-][N+](=O)C1=C(OC)C(OC)=C2OC(=O)C(C(=O)OCC)=CC2=C1 JXAIAZYGEYXKGM-UHFFFAOYSA-N 0.000 description 1
- LFPNYZFIEJHSMC-UHFFFAOYSA-N ethyl 7-hydroxy-6-methoxy-2-oxochromene-3-carboxylate Chemical compound COC1=C(O)C=C2OC(=O)C(C(=O)OCC)=CC2=C1 LFPNYZFIEJHSMC-UHFFFAOYSA-N 0.000 description 1
- NSEBATSRASFYRC-UHFFFAOYSA-N ethyl 7-hydroxy-6-methoxy-8-nitro-2-oxochromene-3-carboxylate Chemical compound COC1=C(O)C([N+]([O-])=O)=C2OC(=O)C(C(=O)OCC)=CC2=C1 NSEBATSRASFYRC-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910001506 inorganic fluoride Inorganic materials 0.000 description 1
- 229930012930 isoflavone derivative Natural products 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 150000003536 tetrazoles Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000006492 vascular dysfunction Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/76—Benzo[c]pyrans
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20001593A FI20001593A (fi) | 2000-07-03 | 2000-07-03 | Comt-entsyymiõ inhiboivaa aktiivisuutta omaavia kumariinijohdannaisia |
| PCT/FI2001/000613 WO2002002548A1 (en) | 2000-07-03 | 2001-06-28 | Coumarin derivatives with comt inhibiting activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK18452002A3 true SK18452002A3 (sk) | 2004-04-06 |
Family
ID=8558717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1845-2002A SK18452002A3 (sk) | 2000-07-03 | 2001-06-28 | Deriváty kumarínu inhibujúce COMT, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6951870B2 (xx) |
| EP (1) | EP1301503B1 (xx) |
| JP (1) | JP4851051B2 (xx) |
| KR (1) | KR20030040225A (xx) |
| CN (1) | CN1199963C (xx) |
| AT (1) | ATE260268T1 (xx) |
| AU (2) | AU2001272597B9 (xx) |
| BG (1) | BG107513A (xx) |
| BR (1) | BR0111969A (xx) |
| CA (1) | CA2414787C (xx) |
| DE (1) | DE60102161T2 (xx) |
| DK (1) | DK1301503T3 (xx) |
| EE (1) | EE200300008A (xx) |
| ES (1) | ES2215919T3 (xx) |
| FI (1) | FI20001593A (xx) |
| HU (1) | HUP0301706A3 (xx) |
| IL (2) | IL153352A0 (xx) |
| MX (1) | MXPA02012657A (xx) |
| NO (1) | NO328699B1 (xx) |
| NZ (1) | NZ523121A (xx) |
| PL (1) | PL359068A1 (xx) |
| PT (1) | PT1301503E (xx) |
| RU (1) | RU2282627C2 (xx) |
| SK (1) | SK18452002A3 (xx) |
| TR (1) | TR200400802T4 (xx) |
| WO (1) | WO2002002548A1 (xx) |
| ZA (1) | ZA200210161B (xx) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR846401A0 (en) * | 2001-10-25 | 2001-11-15 | Novogen Research Pty Ltd | 6-Hydroxy isoflavones, derivatives and medicaments involving same |
| AU2002951833A0 (en) * | 2002-10-02 | 2002-10-24 | Novogen Research Pty Ltd | Compositions and therapeutic methods invloving platinum complexes |
| AU2003265737B2 (en) * | 2002-10-02 | 2008-10-16 | Novogen Research Pty Ltd | Combination chemotherapy compositions and methods |
| CN1506359A (zh) | 2002-12-05 | 2004-06-23 | �й�ҽѧ��ѧԺҩ���о��� | 新的香豆素酰胺衍生物及其制法和其药物组合物与用途 |
| US8080675B2 (en) | 2004-09-21 | 2011-12-20 | Marshall Edwards, Inc. | Chroman derivatives, medicaments and use in therapy |
| ATE532777T1 (de) | 2004-09-21 | 2011-11-15 | Marshall Edwards Inc | Substituierte chromanderivate, medikamente und anwendungen in der therapie |
| MY148644A (en) * | 2005-07-18 | 2013-05-15 | Orion Corp | New pharmaceutical compounds |
| WO2007022946A1 (de) | 2005-08-21 | 2007-03-01 | Abbott Gmbh & Co. Kg | Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
| WO2007124617A1 (fr) * | 2006-04-28 | 2007-11-08 | Institute Of Mataria Medica, Chinese Academy Of Medical Sciences | Dérivés de coumarine, leurs procédés de préparation, compositions pharmaceutiques et utilisations |
| ES2343347B2 (es) * | 2009-01-27 | 2011-12-07 | Universidade De Santiago De Compostela | Uso de derivados de 3-fenilcumarinas 6-sustituidas y preparacion de nuevos derivados. |
| EP2635121B1 (en) | 2010-11-01 | 2020-01-08 | MEI Pharma, Inc. | Isoflavonoid compounds and methods for the treatment of cancer |
| TWI638802B (zh) | 2012-05-24 | 2018-10-21 | 芬蘭商奧利安公司 | 兒茶酚ｏ－甲基轉移酶活性抑制化合物 |
| PL3253208T3 (pl) | 2015-02-02 | 2021-11-08 | Mei Pharma, Inc. | Terapie kombinowane do zastosowania w leczeniu nowotworu piersi |
| CN108698984B (zh) | 2015-12-18 | 2022-05-10 | H·科斯特 | 用作药物、特别是用于治疗帕金森氏病的双环化合物 |
| CN107868069A (zh) * | 2017-10-31 | 2018-04-03 | 山东新华制药股份有限公司 | 7‑羟基‑8‑甲基‑6‑硝基‑2‑氧‑2h‑苯并吡喃‑3‑羧酸的制备工艺 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5035393A (xx) * | 1973-08-01 | 1975-04-04 | ||
| US3973608A (en) | 1973-08-01 | 1976-08-10 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Microbial production of certain isoflavones |
| US5236952A (en) * | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| US5283352A (en) * | 1986-11-28 | 1994-02-01 | Orion-Yhtyma Oy | Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same |
| GB8816519D0 (en) | 1987-07-23 | 1988-08-17 | Ici Plc | Antibiotic compounds |
| HUT63843A (en) | 1992-02-13 | 1993-10-28 | Biosignal Kutato Fejlesztoe Kf | Process for producing new kumarin derivatives and their analogs inhibiting mammal cell proliferation and tumour growth, as well as pharmaceutical comkpositions comprising such compounds |
| JP3166094B2 (ja) * | 1993-09-08 | 2001-05-14 | 森永乳業株式会社 | クマリン誘導体及びそれらの用途 |
| JPH0892157A (ja) | 1994-05-02 | 1996-04-09 | F Hoffmann La Roche Ag | プルプロガリン誘導体 |
| GB9626472D0 (en) | 1996-12-20 | 1997-02-05 | Aperia Anita C | New use of comt inhibitors |
-
2000
- 2000-07-03 FI FI20001593A patent/FI20001593A/fi unknown
-
2001
- 2001-06-28 EE EEP200300008A patent/EE200300008A/xx unknown
- 2001-06-28 JP JP2002507800A patent/JP4851051B2/ja not_active Expired - Fee Related
- 2001-06-28 KR KR1020027017767A patent/KR20030040225A/ko not_active Application Discontinuation
- 2001-06-28 HU HU0301706A patent/HUP0301706A3/hu unknown
- 2001-06-28 SK SK1845-2002A patent/SK18452002A3/sk unknown
- 2001-06-28 AU AU2001272597A patent/AU2001272597B9/en not_active Ceased
- 2001-06-28 CA CA2414787A patent/CA2414787C/en not_active Expired - Fee Related
- 2001-06-28 NZ NZ523121A patent/NZ523121A/en not_active IP Right Cessation
- 2001-06-28 PT PT01951741T patent/PT1301503E/pt unknown
- 2001-06-28 DK DK01951741T patent/DK1301503T3/da active
- 2001-06-28 US US10/312,817 patent/US6951870B2/en not_active Expired - Fee Related
- 2001-06-28 CN CNB018121934A patent/CN1199963C/zh not_active Expired - Fee Related
- 2001-06-28 BR BR0111969-9A patent/BR0111969A/pt not_active IP Right Cessation
- 2001-06-28 EP EP01951741A patent/EP1301503B1/en not_active Expired - Lifetime
- 2001-06-28 AT AT01951741T patent/ATE260268T1/de active
- 2001-06-28 DE DE60102161T patent/DE60102161T2/de not_active Expired - Lifetime
- 2001-06-28 TR TR2004/00802T patent/TR200400802T4/xx unknown
- 2001-06-28 PL PL01359068A patent/PL359068A1/xx not_active Application Discontinuation
- 2001-06-28 MX MXPA02012657A patent/MXPA02012657A/es active IP Right Grant
- 2001-06-28 ES ES01951741T patent/ES2215919T3/es not_active Expired - Lifetime
- 2001-06-28 IL IL15335201A patent/IL153352A0/xx unknown
- 2001-06-28 WO PCT/FI2001/000613 patent/WO2002002548A1/en active IP Right Grant
- 2001-06-28 AU AU7259701A patent/AU7259701A/xx active Pending
- 2001-06-28 RU RU2003102894/04A patent/RU2282627C2/ru not_active IP Right Cessation
-
2002
- 2002-12-10 IL IL153352A patent/IL153352A/en not_active IP Right Cessation
- 2002-12-13 ZA ZA200210161A patent/ZA200210161B/en unknown
- 2002-12-18 NO NO20026095A patent/NO328699B1/no not_active IP Right Cessation
-
2003
- 2003-01-31 BG BG107513A patent/BG107513A/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0757038B1 (en) | Benzamide compound and medicinal use thereof | |
| SK18452002A3 (sk) | Deriváty kumarínu inhibujúce COMT, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie | |
| SK46599A3 (en) | Use of condensated (hetaryl-substituted) 1-benzal-3-pyrazol derivates for treating special diseases of the cardiovascular and the central nervous systems | |
| RU2069662C1 (ru) | Производные пиразоло [1,5-а] пиридина, или их фармацевтически приемлемые соли и способ их получения | |
| HU211647A9 (en) | Phenylcarboxamide compounds which have useful pharmaceutical activity | |
| JP2005089334A (ja) | ８−ヒドロキシアデニン化合物 | |
| AU2001272597A1 (en) | Coumarin derivatives with COMT inhibiting activity | |
| US6903114B2 (en) | Derivatives of naphthalene with COMT inhibiting activity | |
| PL150841B1 (en) | Purine compounds. | |
| JPH02124884A (ja) | Ｎ―置換アミド誘導体 | |
| US5360909A (en) | Phenoxyacetic acid compounds and medical preparations containing them | |
| US20090030049A1 (en) | Medicament for genital herpes | |
| CN101602750B (zh) | 萘基、（取代）芳基、哌嗪基脒类化合物 | |
| CA2439730A1 (en) | Benzofuran derivatives and pharmaceutical compositions containing the same | |
| BG107219A (bg) | Терапевтично приложими нови соли на сск инхибитори, методи за тяхното получаване и фармацевтични състави, които ги съдържат | |
| JP2000109465A (ja) | フェニルピラゾ―ル化合物、製法及び抗高脂血症薬 | |
| EP1844776B1 (en) | Agent for prevention/treatment of disease caused by acyclovir-resistant herpesvirus | |
| CZ284006B6 (cs) | Chinolinové sloučeniny, způsob jejich přípravy a farmaceutické přípravky tyto sloučeniny obsahující | |
| JPH072776A (ja) | アンジオテンシンｉｉ拮抗性ピリジン誘導体 | |
| JPS6325591B2 (xx) | ||
| JP2000281656A (ja) | フェニルアゾール化合物、製造法および抗高脂血症薬 | |
| HU183292B (en) | Process for producing pyrrol-derivatives of myocardium-protecting, antiarrhythmic and thromaocite-aggregation-inhibiting activity and pharmaceutical compositions containing them as active agents |